The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) consists of the entire spectrum of fatty liver disease in patients without significant alcohol consumption, ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) to cirrhosis, with NASH recently shown as an important cause of hepatocellular carcinoma (HCC). There is a close relationship between insulin resistance (IR) and NAFLD, with a five-fold higher prevalence of NAFLD in patients with type 2 diabetes (T2DM) compared to that in patients without T2DM. IR is involved in the progression of disease conditions such as steatosis and NASH, as well as hepatic fibrosis progression. The mechanisms underlying these processes involve genetic factors, hepatic fat accumulation, alterations in energy metabolism, and inflammatory signals derived from various cell types including immune cells. In NASH-associated fibrosis, the principal cell type responsible for extracellular matrix production is the hepatic stellate cell (HSC). HSC activation by IR involves “direct” and “indirect” pathways. This review will describe the molecular mechanisms of inflammation and hepatic fibrosis in IR, the relationship between T2DM and hepatic fibrosis, and the relationship between T2DM and HCC in patients with NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · cited 6×
“Conversely, a FIB-4 with a high cutoff value of 2.67 had a sensitivity of 22% in patients with T2DM and 0% in those without [80].”
MethodInfluentialEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Romeo, S., Kozlitina, J., Xing, C., Pertsemlidis, A., Cox, D., Pennacchio, L. A., Boerwinkle, E., Cohen, J. C., & Hobbs, H. H. (2008) · Nature Genetics · doi:10.1038/ng.257 · Cited by 3,416
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Mechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Younossi, Z. M., Golabi, P., de Avila, L., Paik, J. M., Srishord, M., Fukui, N., Qiu, Y., Burns, L., Afendy, A., & Nader, F. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.021 · Cited by 2,235
Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Younossi, Z., Tacke, F., Arrese, M., Chander Sharma, B., Mostafa, I., Bugianesi, E., Wai‐Sun Wong, V., Yilmaz, Y., George, J., Fan, J., et al. (2019) · Hepatology · doi:10.1002/hep.30251 · Cited by 1,858 · cited 1×
“The prevalence of NAFLD in the world population is estimated to be 25%, whereas the pooled overall NASH prevalence estimated among biopsied NAFLD patients is 59% [4,5].”
BackgroundSingh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748
Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease
Castera, L., Friedrich-Rust, M., & Loomba, R. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.036 · Cited by 1,494
Eddowes, P. J., Sasso, M., Allison, M., Tsochatzis, E., Anstee, Q. M., Sheridan, D., Guha, I. N., Cobbold, J. F., Deeks, J. J., Paradis, V., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.042 · Cited by 1,410
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Liver inflammation and fibrosis
Koyama, Y., & Brenner, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88881 · Cited by 1,295 · cited 2×
“C–C chemokine receptors type 2 (CCR2) and 5 (CCR5) and their ligands CCL2 and CCL5 are implicated in the pathogenesis of liver inflammation and fibrosis, especially in NASH [35].”
BackgroundTilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Speliotes, E. K., Yerges-Armstrong, L. M., Wu, J., Hernaez, R., Kim, L. J., Palmer, C. D., Gudnason, V., Eiriksdottir, G., Garcia, M. E., Launer, L. J., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001324 · Cited by 984
Genetics and epigenetics of NAFLD and NASH: Clinical impact
Eslam, M., Valenti, L., & Romeo, S. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.09.003 · Cited by 971
Fibrosis and adipose tissue dysfunction.
Sun, K., Tordjman, J., Clément, K., & Scherer, P. E. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.06.016 · Cited by 960
Imajo, K., Kessoku, T., Honda, Y., Tomeno, W., Ogawa, Y., Mawatari, H., Fujita, K., Yoneda, M., Taguri, M., Hyogo, H., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.11.048 · Cited by 812
Vilar-Gomez, E., Calzadilla-Bertot, L., Wai-Sun Wong, V., Castellanos, M., Aller-de la Fuente, R., Metwally, M., Eslam, M., Gonzalez-Fabian, L., Alvarez-Quiñones Sanz, M., Conde-Martin, A. F., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.04.034 · Cited by 806
Younossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015) · Hepatology · doi:10.1002/hep.28123 · Cited by 802 · cited 1×
“In one study using data from the Surveillance, Epidemiology, and End Results database that covered a six-year period of time from 2004 to 2009, investigators determined that there was a 9% annual increase in the number of HCC cases attributed to NAFLD [105].”
MethodCell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.018 · Cited by 759
Park, C. C., Nguyen, P., Hernandez, C., Bettencourt, R., Ramirez, K., Fortney, L., Hooker, J., Sy, E., Savides, M. T., Alquiraish, M. H., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.10.026 · Cited by 708
Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis
Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.311 · Cited by 671
Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.019 · Cited by 648
Adiponectin regulation and function
Fang, H., & Judd, R. L. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170046 · Cited by 631
Liu, Y.-L., Reeves, H. L., Burt, A. D., Tiniakos, D., McPherson, S., Leathart, J. B. S., Allison, M. E. D., Alexander, G. J., Piguet, A.-C., Anty, R., et al. (2014) · Nature Communications · doi:10.1038/ncomms5309 · Cited by 623 · cited 1×
“E167K) polymorphism is an independent HCC risk factor is still controversial [103,111,112].”
BackgroundApoptosis and necroptosis in the liver: a matter of life and death
Schwabe, R. F., & Luedde, T. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0065-y · Cited by 582
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Mota, M., Banini, B. A., Cazanave, S. C., & Sanyal, A. J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.02.014 · Cited by 570
Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Khan, R. S., Bril, F., Cusi, K., & Newsome, P. N. (2019) · Hepatology · doi:10.1002/hep.30429 · Cited by 542
Wong, V. W., Chan, W., Chitturi, S., Chawla, Y., Dan, Y. Y., Duseja, A., Fan, J., Goh, K., Hamaguchi, M., Hashimoto, E., et al. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13857 · Cited by 506
Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2
Miura, K., Yang, L., van Rooijen, N., Ohnishi, H., & Seki, E. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00365.2011 · Cited by 503
Kwok, R., Choi, K. C., Wong, G. L.-H., Zhang, Y., Chan, H. L.-Y., Luk, A. O.-Y., Shu, S. S.-T., Chan, A. W.-H., Yeung, M.-W., Chan, J. C.-N., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309265 · Cited by 480
CCR1 and CCR5 promote hepatic fibrosis in mice
Seki, E., De Minicis, S., Gwak, G.-Y., Kluwe, J., Inokuchi, S., Bursill, C. A., Llovet, J. M., Brenner, D. A., & Schwabe, R. F. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37444 · Cited by 431
Apoptotic Body Engulfment by a Human Stellate Cell Line Is Profibrogenic
Canbay, A., Taimr, P., Torok, N., Higuchi, H., Friedman, S., & Gores, G. J. (2003) · Laboratory Investigation · doi:10.1097/01.lab.0000069036.63405.5c · Cited by 417 · cited 2×
“This may be through the release of profibrogenic damageassociated molecular patterns [36,37] or other profibrogenic mediators such as Hh ligands and osteopontin (OPN) [19], or via apoptotic bodies [38,39] that may directly act on HSCs.”
BackgroundHepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis
Wang, X., Zheng, Z., Caviglia, J. M., Corey, K. E., Herfel, T. M., Cai, B., Masia, R., Chung, R. T., Lefkowitch, J. H., Schwabe, R. F., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.016 · Cited by 413
Ratziu, V., Sanyal, A., Harrison, S. A., Wong, V. W., Francque, S., Goodman, Z., Aithal, G. P., Kowdley, K. V., Seyedkazemi, S., Fischer, L., et al. (2020) · Hepatology · doi:10.1002/hep.31108 · Cited by 378
The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis
Huebener, P., Pradere, J.-P., Hernandez, C., Gwak, G.-Y., Caviglia, J. M., Mu, X., Loike, J. D., Jenkins, R. E., Antoine, D. J., & Schwabe, R. F. (2015) · Journal of Clinical Investigation · doi:10.1172/jci76887 · Cited by 354
Koehler, E. M., Plompen, E. P. C., Schouten, J. N. L., Hansen, B. E., Darwish Murad, S., Taimr, P., Leebeek, F. W. G., Hofman, A., Stricker, B. H., Castera, L., et al. (2016) · Hepatology · doi:10.1002/hep.27981 · Cited by 321
Svegliati-Baroni, G., Ridolfi, F., Di Sario, A., Casini, A., Marucci, L., Gaggiotti, G., Orlandoni, P., Macarri, G., Perego, L., Benedetti, A., et al. (1999) · Hepatology · doi:10.1002/hep.510290632 · Cited by 320
Alexander, M., Loomis, A. K., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra, D., Ansell, D., Pasqua, A., Lapi, F., Rijnbeek, P., Mosseveld, M., et al. (2019) · BMC Medicine · doi:10.1186/s12916-019-1321-x · Cited by 317
Limitations of non-invasive tests for assessment of liver fibrosis
Patel, K., & Sebastiani, G. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100067 · Cited by 317
A vicious circle between insulin resistance and inflammation in nonalcoholic fatty liver disease
Chen, Z., Yu, R., Xiong, Y., Du, F., & Zhu, S. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0572-9 · Cited by 316
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
Eslam, M., & George, J. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0212-0 · Cited by 308
The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis
Huebener, P., Pradere, J.-P., Hernandez, C., Gwak, G.-Y., Caviglia, J. M., Mu, X., Loike, J. D., Jenkins, R. E., Antoine, D. J., & Schwabe, R. F. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126975 · Cited by 300
Zhan, S.-S., Jiang, J. X., Wu, J., Halsted, C., Friedman, S. L., Zern, M. A., & Torok, N. J. (2006) · Hepatology · doi:10.1002/hep.21093 · Cited by 284
Daniels, S. J., Leeming, D. J., Eslam, M., Hashem, A. M., Nielsen, M. J., Krag, A., Karsdal, M. A., Grove, J. I., Neil Guha, I., Kawaguchi, T., et al. (2019) · Hepatology · doi:10.1002/hep.30163 · Cited by 273
Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice
Berres, M.-L., Koenen, R. R., Rueland, A., Zaldivar, M. M., Heinrichs, D., Sahin, H., Schmitz, P., Streetz, K. L., Berg, T., Gassler, N., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41732 · Cited by 263
MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals
Donati, B., Dongiovanni, P., Romeo, S., Meroni, M., McCain, M., Miele, L., Petta, S., Maier, S., Rosso, C., De Luca, L., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-04991-0 · Cited by 263
Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis
Zhu, C., Kim, K., Wang, X., Bartolome, A., Salomao, M., Dongiovanni, P., Meroni, M., Graham, M. J., Yates, K. P., Diehl, A. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat0344 · Cited by 250
Critical comparison of elastography methods to assess chronic liver disease
Friedrich-Rust, M., Poynard, T., & Castera, L. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.86 · Cited by 245
Insulin Resistance Accelerates a Dietary Rat Model of Nonalcoholic Steatohepatitis
Ota, T., Takamura, T., Kurita, S., Matsuzawa, N., Kita, Y., Uno, M., Akahori, H., Misu, H., Sakurai, M., Zen, Y., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.10.014 · Cited by 227
Non‐invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE
Doycheva, I., Cui, J., Nguyen, P., Costa, E. A., Hooker, J., Hofflich, H., Bettencourt, R., Brouha, S., Sirlin, C. B., & Loomba, R. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13405 · Cited by 210
Yang, J. D., Ahmed, F., Mara, K. C., Addissie, B. D., Allen, A. M., Gores, G. J., & Roberts, L. R. (2020) · Hepatology · doi:10.1002/hep.30858 · Cited by 209
Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner
Pajvani, U. B., Shawber, C. J., Samuel, V. T., Birkenfeld, A. L., Shulman, G. I., Kitajewski, J., & Accili, D. (2011) · Nature Medicine · doi:10.1038/nm.2378 · Cited by 193
Shirabe, K., Bekki, Y., Gantumur, D., Araki, K., Ishii, N., Kuno, A., Narimatsu, H., & Mizokami, M. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1425-z · Cited by 179
Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD
Tapper, E. B., & Loomba, R. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.10 · Cited by 179
Abe, M., Miyake, T., Kuno, A., Imai, Y., Sawai, Y., Hino, K., Hara, Y., Hige, S., Sakamoto, M., Yamada, G., et al. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-014-1007-2 · Cited by 170
Wagner, M., Corcuera-Solano, I., Lo, G., Esses, S., Liao, J., Besa, C., Chen, N., Abraham, G., Fung, M., Babb, J. S., et al. (2017) · Radiology · doi:10.1148/radiol.2016160863 · Cited by 164
Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD), Nakahara, T., Hyogo, H., Yoneda, M., Sumida, Y., Eguchi, Y., Fujii, H., Ono, M., Kawaguchi, T., Imajo, K., et al. (2014) · Journal of Gastroenterology · doi:10.1007/s00535-013-0911-1 · Cited by 163
Self-citationGut-Brain Glucose Signaling in Energy Homeostasis
Soty, M., Gautier-Stein, A., Rajas, F., & Mithieux, G. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.032 · Cited by 163
Ballestri, S., Nascimbeni, F., Romagnoli, D., & Lonardo, A. (2016) · Hepatology Research · doi:10.1111/hepr.12656 · Cited by 158
Gawrieh, S., Dakhoul, L., Miller, E., Scanga, A. E., deLemos, A. S., Kettler, C. D., Burney, H. N., Liu, H., Abu‐Sbeih, H., Chalasani, N., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15464 · Cited by 147
Platelet count for predicting fibrosis in nonalcoholic fatty liver disease
Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD), Yoneda, M., Fujii, H., Sumida, Y., Hyogo, H., Itoh, Y., Ono, M., Eguchi, Y., Suzuki, Y., Aoki, N., et al. (2011) · Journal of Gastroenterology · doi:10.1007/s00535-011-0436-4 · Cited by 143
Self-citationHelsley, R. N., Varadharajan, V., Brown, A. L., Gromovsky, A. D., Schugar, R. C., Ramachandiran, I., Fung, K., Kabbany, M. N., Banerjee, R., Neumann, C. K. A., et al. (2019) · eLife · doi:10.7554/elife.49882 · Cited by 131
Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
Rhee, E. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.226 · Cited by 119
Loomba, R. S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.028 · Cited by 115
Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis
Bengtsson, B., Stal, P. I., Wåhlin, S., Björkström, N. K., & Hagström, H. (2019) · Liver International · doi:10.1111/liv.14087 · Cited by 112
Ranjbar, G., Mikhailidis, D. P., & Sahebkar, A. (2019) · Metabolism · doi:10.1016/j.metabol.2019.154001 · Cited by 110
Selective insulin resistance with differential expressions of IRS-1 and IRS-2 in human NAFLD livers
Honma, M., Sawada, S., Ueno, Y., Murakami, K., Yamada, T., Gao, J., Kodama, S., Izumi, T., Takahashi, K., Tsukita, S., et al. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0062-9 · Cited by 108
Fujii, H., Imajo, K., Yoneda, M., Nakahara, T., Hyogo, H., Takahashi, H., Hara, T., Tanaka, S., Sumida, Y., Eguchi, Y., et al. (2019) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14595 · Cited by 104
Self-citationDivergent Roles of IRS (Insulin Receptor Substrate) 1 and 2 in Liver and Skeletal Muscle
Eckstein, S. S., Weigert, C., & Lehmann, R. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170426142826 · Cited by 98
Roulot, D. M., Roudot‐Thoraval, F., Nkontchou, G., Kouacou, N., Costes, J., Elourimi, G., Clésiau, H. L., Ziol, M., & Beaugrand, M. (2017) · Liver International · doi:10.1111/liv.13481 · Cited by 97
Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study
Cui, J. Y., Chen, C., Lo, M., Schork, N. J., Bettencourt, R., Gonzalez, M. P., Bhatt, A., Hooker, J. C., Shaffer, K. M., Nelson, K. E., et al. (2016) · Hepatology · doi:10.1002/hep.28674 · Cited by 90
Oeda, S., Takahashi, H., Imajo, K., Seko, Y., Ogawa, Y., Moriguchi, M., Yoneda, M., Anzai, K., Aishima, S., Kage, M., et al. (2019) · Journal of Gastroenterology · doi:10.1007/s00535-019-01635-0 · Cited by 85
MBOAT7 Down-Regulation by Hyperinsulinemia Induces Fat Accumulation in Hepatocytes
Meroni, M., Dongiovanni, P., Longo, M., Carli, F., Baselli, G., Rametta, R., Pelusi, S., Badiali, S., Maggioni, M., Gaggini, M., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2020.102658 · Cited by 85
Dongiovanni, P., Meroni, M., Baselli, G., Bassani, G. A., Rametta, R., Pietrelli, A., Maggioni, M., Facciotti, F., Trunzo, V., Badiali, S., et al. (2017) · Clinical Science · doi:10.1042/cs20170175 · Cited by 81
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Sumida, Y., Yoneda, M., Tokushige, K., Kawanaka, M., Fujii, H., Yoneda, M., Imajo, K., Takahashi, H., Eguchi, Y., Ono, M., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061907 · Cited by 78
Self-citationHepatocellular carcinoma and non-alcoholic fatty liver disease
Golabi, P., Rhea, L. P., Henry, L. L., & Younossi, Z. M. (2019) · Hepatology International · doi:10.1007/s12072-019-09995-8 · Cited by 75
Yoneda, M., Imajo, K., Takahashi, H., Ogawa, Y., Eguchi, Y., Sumida, Y., Yoneda, M., Kawanaka, M., Saito, S., Tokushige, K., et al. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1414-2 · Cited by 73
A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers
Kamada, Y., Ono, M., Hyogo, H., Fujii, H., Sumida, Y., Mori, K., Tanaka, S., Yamada, M., Akita, M., Mizutani, K., et al. (2015) · Hepatology · doi:10.1002/hep.28002 · Cited by 72
Self-citationIs cryptogenic cirrhosis different from NASH cirrhosis?
Thuluvath, P. J., Kantsevoy, S. V., Thuluvath, A. J., & Savva, Y. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.018 · Cited by 67
Hepatocyte Injury and Hepatic Stem Cell Niche in the Progression of Non-Alcoholic Steatohepatitis
Overi, D., Carpino, G., Franchitto, A., Onori, P., & Gaudio, E. (2020) · Cells · doi:10.3390/cells9030590 · Cited by 66
Alkayyali, T., Qutranji, L., Kaya, E., Bakır, A., & Yilmaz, Y. N. (2020) · Acta Diabetologica · doi:10.1007/s00592-019-01467-7 · Cited by 63
Vily‐Petit, J., Soty, M., Silva, M., Raffin, M., Gautier‐Stein, A., Rajas, F., & Mithieux, G. (2020) · Gut · doi:10.1136/gutjnl-2019-319745 · Cited by 63
Fujimori, N., Umemura, T., Kimura, T., Tanaka, N., Sugiura, A., Yamazaki, T., Joshita, S., Komatsu, M., Usami, Y., Sano, K., et al. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i11.1239 · Cited by 62
Tokushige, K., Hyogo, H., Nakajima, T., Ono, M., Kawaguchi, T., Honda, K., Eguchi, Y., Nozaki, Y., Kawanaka, M., Tanaka, S., et al. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-015-1129-1 · Cited by 61
Self-citationOkanoue, T., Ebise, H., Kai, T., Mizuno, M., Shima, T., Ichihara, J., & Aoki, M. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1355-9 · Cited by 59
Umano, G. R., Caprio, S., Sessa, A. D., Chalasani, N., Dykas, D. J., Pierpont, B. M., Bale, A. E., & Santoro, N. (2018) · The American Journal of Gastroenterology · doi:10.1038/ajg.2018.1 · Cited by 58
Liang, T., Zhang, Q., Sun, W., Xin, Y., Zhang, Z., Tan, Y., Zhou, S., Zhang, C., Cai, L., Lu, X., et al. (2015) · Toxicology Letters · doi:10.1016/j.toxlet.2015.01.010 · Cited by 56
Musso, G., Cipolla, U., Cassader, M., Pinach, S., Saba, F., Michieli, F. D., Paschetta, E., Bongiovanni, D., Framarin, L., Leone, N., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m075028 · Cited by 55
Dongiovanni, P., Rametta, R., Meroni, M., & Valenti, L. V. C. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1110018 · Cited by 54
Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis
Kamada, Y., Ono, M., Hyogo, H., Fujii, H., Sumida, Y., Yamada, M., Mori, K., Tanaka, S., Maekawa, T., Ebisutani, Y., et al. (2017) · Hepatology Communications · doi:10.1002/hep4.1080 · Cited by 52
Self-citationSingh, A., Gosai, F., Siddiqui, M. T., Gupta, M., López, R., Lawitz, E., Poordad, F. F., Carey, W. W., McCullough, A. J., & Alkhouri, N. (2020) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001339 · Cited by 48
Nishikawa, H., Enomoto, H., Iwata, Y., Kishino, K., Shimono, Y., Hasegawa, K., Nakano, C., Takata, R., Yoh, K., Nishimura, T., et al. (2016) · Hepatology Research · doi:10.1111/hepr.12662 · Cited by 47
Applicability of BARD score to Japanese patients with NAFLD
Fujii, H., Enomoto, M., Fukushima, W., Tamori, A., Sakaguchi, H., & Kawada, N. (2009) · Gut · doi:10.1136/gut.2009.182758 · Cited by 45
Self-citationRametta, R., Mozzi, E., Dongiovanni, P., Motta, B. M., Milano, M., Roviaro, G., Fargion, S. R., & Valenti, L. V. C. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.181 · Cited by 44
Wang, Y.-H., Sun, Y., Zuo, L., Wang, Y., & Huang, Y. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.10.003 · Cited by 37
Kang, K. A., Jun, D. W., Kim, M. S., Kwon, H., & Nguyen, M. H. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15626 · Cited by 36
Enooku, K., Kondo, M., Fujiwara, N., Sasako, T., Shibahara, J., Kado, A., Okushin, K., Fujinaga, H., Tsutsumi, T., Nakagomi, R., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1472-0 · Cited by 35
Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes
Alkhouri, N., Poordad, F. F., & Lawitz, E. (2018) · Hepatology Communications · doi:10.1002/hep4.1195 · Cited by 34
Honda, Y., Imajo, K., Kobayashi, T., Kessoku, T., Ogawa, Y., Tomeno, W., Yoneda, M., Kobayashi, N., Saito, S., & Nakajima, A. (2019) · Hepatology Research · doi:10.1111/hepr.13382 · Cited by 33
Mosca, A., Comparcola, D., Romito, I., Mantovani, A., Nobili, V., Byrne, C. D., Alisi, A., & Targher, G. (2019) · Liver International · doi:10.1111/liv.14225 · Cited by 32
Jung, K. Y., Cho, S. Y., Kim, H. J., Kim, S. B., & Song, I. H. (2014) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000065 · Cited by 27
Villar-Lorenzo, A., Rada, P., Rey, E., Marañón, P., Arroba, A. I., Santamaría, B., Sáiz, J., Rupérez, F. J., Barbas, C., García‐Monzón, C., et al. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.038810 · Cited by 19
Kiss, K., Regős, E., Rada, K. R., Firneisz, G., Baghy, K., & Kovalszky, I. (2018) · Pathology & Oncology Research · doi:10.1007/s12253-018-0458-9 · Cited by 6
Cited by
Kawaguchi, T., Charlton, M., Kawaguchi, A., Yamamura, S., Nakano, D., Tsutsumi, T., Zafer, M., & Torimura, T. (2021) · Seminars in Liver Disease · doi:10.1055/s-0041-1723751 · Cited by 122
Lin, I.-T., Lee, M.-Y., Wang, C.-W., Wu, D.-W., & Chen, S.-C. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18030857 · Cited by 69
Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome
Wang, D., & He, B. (2022) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s362424 · Cited by 28
Metadata
- Authors
- Fujii, H., Kawada, N., & Japan Study Group of NAFLD (JSG-NAFLD)
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-05-29
- Volume
- 21
- Issue
- 11
- Pages
- 3863
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3029895132
- Cited by
- 299
- References
- 108
- FWCI
- 17.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.